GERMANTOWN, Md., Aug. 17, 2020 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with Precigen’s PRGN-2009, a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse™ platform designed to activate the immune system to recognize and target HPV+ solid tumors (clinical trial identifier: NCT04432597). HPV-associated cancers represent a significant health burden in indications such as head and neck, cervical, vaginal and anal cancer.
{iframe}https://www.biospace.com/article/releases/precigen-announces-first-patient-dosed-in-phase-i-ii-study-of-first-in-class-prgn-2009-adenoverse-immunotherapy-to-treat-hpv-associated-cancers/{/iframe}